Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VP-102 Cantharidin, topical film forming solution, VP-102 - Cantharidin, Topical Film Forming Solution, VP-102- Cantharidin, Film Forming
VP-102 Cantharidin, film forming · 2 trials · 1 indication
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS).
| Arm | Type | Description |
|---|---|---|
| VP-102 | ACTIVE_COMPARATOR | VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% \[w/v\] cantharidin) solution. |
| Placebo | PLACEBO_COMPARATOR | Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102. |
| Name | Type | Description |
|---|---|---|
| VP-102 - Cantharidin, Topical Film Forming Solution | COMBINATION_PRODUCT | VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals. |
| Placebo -Topical Film Forming Solution without VP-102 | COMBINATION_PRODUCT | Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals. |
Inclusion Criteria: To qualify for inclusion in this study, subjects must: 1. Be healthy subjects, at least 2 years of age or older. 2. Consent to having all molluscum lesions treated and the physician must be willing to treat all molluscum lesions initially present. Lesions within 10mm of the eye...
VP-102 Cantharidin, film forming is being developed for the treatment of molluscum contagiosum, a viral skin infection that causes raised, pearl-like bumps. It is a small molecule therapy in the dermatology therapeutic area. Verrica Pharmaceuticals Inc. is developing it as a topical film forming solution applied directly to the skin.
VP-102 Cantharidin, film forming is developed by Verrica Pharmaceuticals Inc., which trades on the Nasdaq under the ticker VRCA. The company is focused on dermatology therapeutics, and VP-102 is its cantharidin-based topical film forming solution candidate for molluscum contagiosum.
VP-102 Cantharidin, film forming is in Phase 3 clinical development. It is an investigational therapy and has not been approved by the FDA. Two Phase 3 trials have been completed, and no trials are currently active. Both completed studies were randomized, double-blind, and placebo-controlled.
VP-102 Cantharidin, film forming has been studied in two completed Phase 3 trials: NCT03377803, titled Cantharidin Application in Molluscum Patients, which enrolled 262 participants, and NCT03377790, titled Cantharidin Application in Molluscum Patients-1, which enrolled 266 participants. Both trials were conducted in the United States and enrolled patients aged 2 years and older.
Yes. VP-102 Cantharidin, film forming is also known as VP-102, VP-102 Cantharidin, topical film forming solution, VP-102 - Cantharidin, Topical Film Forming Solution, and VP-102 - Cantharidin, Film Forming. These names refer to the same investigational cantharidin-based topical product developed by Verrica Pharmaceuticals Inc. for molluscum contagiosum.
The two completed Phase 3 trials of VP-102 Cantharidin, film forming enrolled a total of 528 participants. NCT03377803 enrolled 262 patients and NCT03377790 enrolled 266 patients. Both studies were randomized, double-blind, placebo-controlled trials in molluscum contagiosum conducted in the United States, with participants aged 2 years and older.